Investors Animated Over Aclaris Oral Rheumatoid Arthritis Therapy
MK2 Inhibitor Impresses In Phase IIa
Great progress has been made in the treatment of RA with biologics and JAK inhibitors but there is a space for effective small-molecule therapies and Aclaris hopes to fill it with ATI-450.
